Considering cemiplimab is an IgG4 monoclonal antibody and the known physiological relationship of IgG proteins [18], endogenous or otherwise, with albumin [17], it is reasonable to expect the observed relationship between high baseline IgG levels and increasing cemiplimab CL in patients with advanced CSCC. Here, ALB is linked to skin squamous cell carcinoma.